POST-ACUTE COVID-19 SYNDROME (PACS)

Advisory Council to the Director Dec 10, 2020

Walter J. Koroshetz, MD Director, National Institute of Neurological Disorders and Stroke

TRANS-NIH POST-ACUTE COVID SEQUELAE TASK FORCE AMY PATTERSON /NHLBI

- Komal Arora, NHLBI
- Audie Atienza, NCATS
- Karin Bok, VRC
- Joseph Breen, NIAID
- Patti Brennan, NLM
- William Cefalu, NIDDK
- Stephen Chanock, NCI
- Sean Coady, NHLBI
- Richard Conroy, OD
- Rosaly Correa-De-Araujo, NIA
- Janelle Cortner, NCI
- Gaya Dowling, NIDA
- Robert Eisinger, NIAID
- Rachel Fleurence, OD
- Michelle Freund, NIDA

- Ken Gersing, NCATS
- David Goff, NHLBI
- Leanne Goldstein, OD, IMOD
- Susan Gregurik, OD, DPCPSI
- James Gulley, NCI
- Even Hadley, NIA
- Justin Hentges, OD, ALL
- Stephen Hewitt, NCI
- Keith Hoots, NHLBI
- Steve James, NIDDK
- Kathy Jung, NIAAA
- Bill Kapogiannis, NICHD
- Barbara Karp, NINDS
- Jim Kiley, NHLBI
- Walter Koroshetz, NINDS

- Mike Kurilla, NCATS
- Andrea Lerner, NIAID
- Teri Manolio, NHGRI
- Eliezer Masliah, NIA
- Amanda Melillo, NIDCR
- Sam Michael, NCATS
- Gina Montealegre, NIAID
- Lori Newman, NIAID
- Jenna Norton, NIDDK
- Luigi Notarangelo, NIAID
- Tessie October, NICHD
- April Oh, NCI
- Amy Patterson, NHLBI
- Eliseo Perez-Stable, NIMHD
- Lisa Postow, NHLBI

- Joni Rutter, NCATS
- Sheri Schully, OD, ALL
- Ivonne Schulman, NIDDK
- Christine Sizemore, FIC
- Mike Sneller, NIAID
- Rob Star, NIDDK
- Susan Sullivan, NIDCD
- Alastair Thomson, NHLBI
- Jackie Ward, NINDS
- Wendy Weber, NCCIH
- Andrew Weitz, NIBIB
- Carolyn Williams, NIAID
- Dana Wolff-Hughes, OD
- May Wong, NINDS


1) Problem statement

- 2) Clinical manifestations and knowledge gaps
- 3) Leveraging our assets and strengths

Post-Acute COVID-19 Syndrome


July 31, 2020 Science From 'Brain Fog' to Heart Damage, **COVID-19's Lingering Problems Alarm Scientists**

J Couzin-Frankel



Long-Term Effects of Covid-19 Infection

COVID-19 Affects Multiple Organs




CLINICAL MANIFESTATIONS AND KNOWLEDGE GAPS


COVID-19: Persistent Symptoms in Hospitalized Patients *A Multi-Organ, Multi-System Clinical Presentation*

120 patients (mean = 111 days post admission)


Persistent symptoms

- Fatigue 55%
- Difficulty breathing 42%
- Memory loss 34%
- Sleep disorder 32%
- Attention disorder 27%
- Significant hair loss 20%
- Cough 17%
- Loss of smell 13%
- Chest pain 11%
- Loss of taste 11%





143 patients (mean 60 days post onset)




Carifi, et. al. JAMA. 2020;324(6):603-605. doi:10.1001/jama.2020.12603

COVID-19: Persistent Symptoms and Health-related Quality of Life¹

A Multi-Organ, Multi-System Clinical Presentation

120 patients (mean = 111 days after admission for COVID-19)



Professional and physical activities

- Not yet resumed to sports (engaged regularly pre-COVID) 28%
- Slower walking 29%
- Not yet returned to work (worked pre-COVID) 32%


¹Letter to the Editor, Journal of Infection, **Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19,** Eve Garrigues et al. <u>https://doi.org/10.1016/j.jinf.2020.08.029</u> CDC

Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™

July 31, 2020

Morbidity and Mortality Weekly Report (MMWR)

Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020




MW Tenforde, LR Feldstein et al. for the IVY Network Investigators and CDC COVID-19 Response Team


Among symptomatic <u>non hospitalized</u> patients with positive test for SARS-CoV-2, 35% not returned to baseline health <u>2-3 weeks</u> after testing

- Older age and comorbidities associated with lack of return to baseline health
- 19% of young adults (18-34) with no comorbidities had not returned to baseline health
- In contrast 90% of influenza outpatients recover within 2 weeks


New diagnoses of anxiety, insomnia, dementia, and mood disorders, as well as psychiatric disorders in general, were increased after COVID-19 illness




Cross-talk among injured organs might explain post-acute COVID syndrome









Microbial metabolites Cytokines Other circulating factors Immune system dysfunction













Published online July 27, 2020


JAMA Cardiology | Original Investigation

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

Valentina O. Puntmann, MD, PhD; M. Ludovica Carerj, MD; Imke Wieters, MD; Masia Fahim; Christophe Arendt, MD; Jedrzej Hoffmann, MD; Anastasia Shchendrygina, MD, PhD; Felicitas Escher, MD; Mariuca Vasa-Nicotera, MD; Andreas M. Zeiher, MD; Maria Vehreschild, MD; Eike Nagel, MD

cMRI revealed cardiac abnormalities in 78%, and gadolinium enhancement in 60%, (N-100), median 72d p dx.

- Independent of preexisting conditions, severity, and overall course of acute illness, and time from original diagnosis
- Lower EF, Higher LV volume, Higher hsTroponin
- 3 patients biopsied, demonstrate inflammatory infiltrates, no virus



Research Letter

September 11, 2020

Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection

Saurabh Rajpal, MBBS, MD¹; Matthew S. Tong, DO¹; James Borchers, MD, MPH¹; <u>et al</u>

15% of Ohio State University athletes had myocarditis after mild COVID-19, and fully half had CMR abnormalities


Cardiac Involvement in COVID-19

EDITORIAL

Coronavirus Disease 2019 (COVID-19) and the Heart– Is Heart Failure the Next Chapter?

Clyde W. Yancy, MD, MSc; Gregg C. Fonarow, MD

Published Online: July 27,2020 doi:10.1001/jamacardio.2020.3575



- Autopsy reports suggest direct cardiac involvement
 - Lindner showed virus in myocardium in majority of 39 autopsy cases with evidence of viral replication:
 - Direct viral infection leading to myocardial injury??
 - Other reports have also shown myocardium infiltration of both innate and adaptive immune cells:
 - Potential for cardiac fibrosis and decrease cardiac function in the long term??
- Conclusion: Long-term follow-up of recovered COVID-19 patients is necessary to assess risk of heart failure and other chronic CV complications

JAMA Cardiol. doi:10.1001/jamacardio.2020.3557 JAMA Cardiol. doi:10.1001/jamacardio.2020.3551

Inflammation and potential remodeling mechanisms in COVID-19 heart.

Potential common mechanisms between ischemic injury and COVID-19 induced cardiac remodeling; Unudurthi S. Life Sciences 2020; 260: 118482

COVID-19: Long-term lung sequelae




Fig. 2. Follow-up thin-section CT imaging of 63-year-old man with confirmed COVID-

- Carvalho-Schneider et al. followed 150 patients with noncritical COVID-19 for 2 months after symptoms onset
 - Persistent dyspnea: 36.7% pts at 30d, 30% pts at 60d
- Conclusion: A prolonged medical follow-up of patients with COVID-19 seems essential, whatever the initial clinical presentation (never admitted patients in this case) https://pubmed.ncbi.nlm.nih.gov/33031948/ Oct 2020
- Zhao et al. analyzed 55 COVID-19 survivors (non-critical cases)
 3 months after hospital discharge
 - Radiological abnormalities: 71% pts
 - Lung function abnormalities: 25% pts
 - Elevated D-dimer on admission predictive of impaired DLCO at 3 months post-d/c (in some pts, only abnormality)
- Conclusion: It is necessary to follow up COVID-19 patients to appropriately manage persistent or emerging long-term sequelae

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361108/ July 2020

Nervous System and COVID-19

Manifestations during infection

- Stroke- large & small vessel occlusion, microbleeds
- Confusion and depressed level of consciousness
- Loss of smell
- Muscle/Nerve pain and weakness
- Meningitis/encephalitis
- Seizures
- Asymptomatic hypoxia

Rare Post-viral syndromes


- Delayed injury to brain and spinal cord (multiple sclerosis- like).
- Delayed injury to nerves (ie. Guillain Barre Syndrome)
- Parkinsonism


nature neuroscience

ARTICLES https://doi.org/10.1038/s41593-020-00758-5



Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19






LR Feldstein, S Li et al., for the Overcoming COVID-19 Investigators, and the CDC COVID-19 Response Team

- 186 patients in 26 states, median age 8.3 years
- **80%** required ICU care, 20% required mechanical ventilation
- **71%** with involvement of at least 4 organ systems
- **73%** with no underlying conditions

Health Disparities in COVID-19 Risk and Mortality

Black & Indigenous Americans experience highest death tolls from Covid-19 Cumulative actual Covid-19 mortality rates per 100,000, by race and ethnicity, April 13-Nov. 10, 2020



Note: All intervals are 14 days apart, except for 5/11-5/26, which is a 15-day period. 9/1, 9/29 and 10/27 data has been interpolated. Pacific Islander data prior to 10/13 did not include Hawaii, as it was not releasing data; its inclusion resulted in an overall drop in the Pacific Islander rate, which begins a new series at 10/13.

Source: <u>APM Research Lab</u>. Get the data. Created with <u>Datawrapper</u>.


Predisposing Conditions

- Cancer
 - **Chronic Kidney Disease**
- COPD
- Heart Conditions
- Obesity
- Pregnancy
- Sickle Cell Disease
- Smoking
- Type 2 Diabetes

https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html

What we need to understand about recovery

- What is the spectrum of clinical "recovery" from COVID-19 infection?
 - Of those with symptoms 2-3 weeks post infection the rate of improvement is not yet known.
- What interventions might enhance or hasten recovery?
 - In the immediate post infection phase as well as in the more chronic phase
- What is the spectrum of tissue injury due to COVID-19 infection?
 - Are the various tissue injuries reversible, static, or contribute to progressive organ dysfunction
 - How to identify those with tissue injury in heart, lung, nervous system, kidney
- Will unabated symptoms lead to chronic illness(s) in a subset of people?
 - If so, what is its pathophysiology (s).
 - Is so, what are the drivers of special vulnerability or resilience across the lifespan and in special populations
- Will COVID-19 infection predispose people to other diseases in the future?



Preparing for the Possibility of a Post-COVID Storm

- Current expectation is that up to tens of thousands could suffer from sequelae of acute infection with COVID-19
- Time is of the essence interventions are expected to have a greater effect the earlier they are employed



• The multi-organ involvement calls for a coordinated research program drawing on the expertise in multiple NIH Institutes and Centers

LEVERAGING OUR ASSESTS AND STRENGTHS A Few Examples

NIH Clinical Research Strategy to Understand and Treat Post-acute Sequelae of COVID-19

Note: Includes existing and new assets

Evaluation of Treatment and Preventive Strategies for Post-acute COVID-19 Sequelae

Longitudinal Community-Based Cohorts

Large Scale
 EHR-/Health Systems-based
 Cohorts

Longitudinal
 Deeply Phenotyped
 Community-based
 Cohorts

Case-based Registry Cohort of Persons with hx SARs COV-2 Infection

- Individuals Enrolled in NIH COVID-19 Clinical Trials
- Individuals Enrolled in NIH COVID-19 Case Registries/Observational Studies/Clinics

Data Coordination/Harmonization and Analytics Framework

NIAID: Observational Cohorts

- International Observational Study of Outpatients With SARS-CoV-2 Infection
- PREVAIL-XI: PREVAIL COVID-19 Observational Study
- Chasing COVID Cohort
- Immunophenotyping in a COVID-19 Cohort (IMPACC)
- Pediatric Research Immune Network on SARS-CoV-2 and MIS-C (PRISM)
- Observational study at San Antonio VA
- EHR based
 - Corona infectious virus epidemiology team (CIVETs)
 - Big Data Driven Clinical Informatics & Surveillance (BDD-CIS) project

Collaborative Cohort of Cohorts for COVID-19 Research (C4R)

- 70,000+ participants from 14+ longstanding longitudinal population- and disease-based cohorts
 - Highly diverse with multi-racial, multi-ethnic populations
 - Broad age range, national span of geographic reach
 - Enriched for at-risk populations (e.g., pre-existing lung disease)
 - Genotyped and deep phenotyping across multiple domains
 - Imaging, biomarkers, social determinants, lung function, anthropometry, vascular function, cognition, genetics and other -omics



- Leverage existing infrastructure, processes, data, and biospecimens from available cohorts/existing patient populations
 - Embed systematic protocolized assessment in existing cohorts
 - Include multiple nested sub-studies
- Collaboration with NHLBI, NINDS, and NIA

NHLBI platforms leveraged for development of COVID-19 long-term follow-up cohorts

Registry and observational cohort study (CORAL) follow-up of COVID-19 inpatients (n = 3,000) leveraging critical care network

- Clinical characteristics, Rx, biology, and outcomes using retro/prospective methods
- Deidentified repository of clinical, imaging, and biologic data and biospecimens

Serves as a pilot for:

Larger Scale Multicenter Prospective COVID-19 Registry Cohort

- Leveraging the diagnosis, screening, and referral cores and clinical centers
- COVID-19 enriched and diverse cohort spanning pre-hospital, hospital, and postdischarge enrollment
- Systematic and protocolized collection of health data, biospecimens, and imaging on post-COVID pts for long-term, post-infection follow-up studies; utilizing full spectrum of data (EHR mining to IPLD)
- Fully consented for data sharing and follow-up

NIAID: A Longitudinal Study of COVID-19 Sequelae and Immunity

- Adults who have recovered from COVID-19 or were in close contact with someone with COVID-19 but did not become infected
- Evaluation includes history, physical exam, mental health exam, imaging and functional tests, laboratory draws
- Study visits at NIH Clinical Center every 6 months for 3 years
- Goal enrollment: 900

Funded programs to assess long-term neurological effects of COVID-19

- Natural History of Post-Coronavirus Disease 19 Convalescence Avi Nath (NINDS), Brian Walitt (NINR)
 - To observe and describe the range of medical syndromes that occur following an acute COVID-19 infection in1000 adults within six months of their convalescence from an acute COVID-19 infection
- Observational Study of Neurologic Function after COVID-19 Infection Avi Nath, Bryan Smith (NINDS)
 - To investigate brain MRI and components of neurologic function in those with prior SARS-CoV-2 infection and persistent neurologic symptoms
- NIH COVID-19 NeuroDataBank and NeuroBioBank (at NYU Langone)
 - Building a national (NeuroDatabank and BioBank) to document and study neurological complications of COVID
- Projects (through supplements)
 - 2 studies examining <u>cognitive sequelae</u> of the biological effects of COVID-19 on the nervous system-cognitive batteries every 3 months for one year via phone to determine cognitive trajectories over time
 - <u>Neurofilament light chain (NfL) protein in predicting long term cognitive</u>, behavioural and functional prognosis for ICU COVID patients
 - Add-on study to college student cohort (followed for post EBV <u>chronic fatigue</u> syndrome) to assess long-term health post COVID-19

* * *	GOAL	To improve understanding of and develop strategies to treat and prevent post-acute manifestations of SARS-CoV-2 infection through a multi-pronged research framework
Ť ŤŤŤŤŤ	Understand	COVID-19 clinical sequelae, risk factors for illness, severity, outcomes
	Recognize	SARS-CoV-2 infected individuals at risk for post-acute manifestations
5	Identify	Pathogenic mechanisms and therapeutic targets
	Develop	Therapeutic strategies for people with post-acute sequelae

DISCUSSION